Resistance to recombinant human erythropoietin therapy in haemodialysis patients: Focus on inflammatory cytokines, leukocyte activation, iron status and erythrocyte damage
Autor(a) principal: | |
---|---|
Data de Publicação: | 2009 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.14/3025 |
Resumo: | Anaemia is a common complication in haemodialysis patients. This condition is associated to a decreased bone marrow production of erythrocytes, mainly due to the inability of the failing kidneys to secrete erythropoietin (EPO). The introduction of recombinant human EPO (rhEPO) therapy led to a significant reduction in anaemia and improved patients’ quality of life. However, there is a marked variability in the sensitivity to rhEPO, with up to 10-fold variability in dose requirements to achieve correction of anaemia. Approximately 5-10% of the patients show a marked resistance to rhEPO therapy. rhEPO resistance is associated to an increased morbidity and mortality of haemodialysis patients. In this paper a revision of the mechanisms underlying resistance to rhEPO therapy will be performed, with particular emphasis on inflammatory cytokines, leukocyte activation, iron status, and erythrocyte damage. |
id |
RCAP_0f87def220b64dd59d863d3869848297 |
---|---|
oai_identifier_str |
oai:repositorio.ucp.pt:10400.14/3025 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Resistance to recombinant human erythropoietin therapy in haemodialysis patients: Focus on inflammatory cytokines, leukocyte activation, iron status and erythrocyte damageHaemodialysisResitance to rhEPO therapyErythropoietinInflammationLeukocyte activationIron statusErythrocyte damageAnaemia is a common complication in haemodialysis patients. This condition is associated to a decreased bone marrow production of erythrocytes, mainly due to the inability of the failing kidneys to secrete erythropoietin (EPO). The introduction of recombinant human EPO (rhEPO) therapy led to a significant reduction in anaemia and improved patients’ quality of life. However, there is a marked variability in the sensitivity to rhEPO, with up to 10-fold variability in dose requirements to achieve correction of anaemia. Approximately 5-10% of the patients show a marked resistance to rhEPO therapy. rhEPO resistance is associated to an increased morbidity and mortality of haemodialysis patients. In this paper a revision of the mechanisms underlying resistance to rhEPO therapy will be performed, with particular emphasis on inflammatory cytokines, leukocyte activation, iron status, and erythrocyte damage.OmniScientiaVeritati - Repositório Institucional da Universidade Católica PortuguesaCosta, ElísioBelo, LuísQuintanilha, AlexandreSantos-Silva, Alice2010-10-16T16:46:14Z20092009-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.14/3025engCOSTA, Elísio; BELO, Luís - Resistance to recombinant human erythropoietin therapy in haemodialysis patients: Focus on inflammatory cytokines, leukocyte activation, iron status and erythrocyte damage. Journal of Nephrology and Renal Transplantation. ISSN 1918-025X. Vol. 2, n.º 3 (2009), p. 66–83info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-12T17:09:42Zoai:repositorio.ucp.pt:10400.14/3025Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T18:05:13.367142Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Resistance to recombinant human erythropoietin therapy in haemodialysis patients: Focus on inflammatory cytokines, leukocyte activation, iron status and erythrocyte damage |
title |
Resistance to recombinant human erythropoietin therapy in haemodialysis patients: Focus on inflammatory cytokines, leukocyte activation, iron status and erythrocyte damage |
spellingShingle |
Resistance to recombinant human erythropoietin therapy in haemodialysis patients: Focus on inflammatory cytokines, leukocyte activation, iron status and erythrocyte damage Costa, Elísio Haemodialysis Resitance to rhEPO therapy Erythropoietin Inflammation Leukocyte activation Iron status Erythrocyte damage |
title_short |
Resistance to recombinant human erythropoietin therapy in haemodialysis patients: Focus on inflammatory cytokines, leukocyte activation, iron status and erythrocyte damage |
title_full |
Resistance to recombinant human erythropoietin therapy in haemodialysis patients: Focus on inflammatory cytokines, leukocyte activation, iron status and erythrocyte damage |
title_fullStr |
Resistance to recombinant human erythropoietin therapy in haemodialysis patients: Focus on inflammatory cytokines, leukocyte activation, iron status and erythrocyte damage |
title_full_unstemmed |
Resistance to recombinant human erythropoietin therapy in haemodialysis patients: Focus on inflammatory cytokines, leukocyte activation, iron status and erythrocyte damage |
title_sort |
Resistance to recombinant human erythropoietin therapy in haemodialysis patients: Focus on inflammatory cytokines, leukocyte activation, iron status and erythrocyte damage |
author |
Costa, Elísio |
author_facet |
Costa, Elísio Belo, Luís Quintanilha, Alexandre Santos-Silva, Alice |
author_role |
author |
author2 |
Belo, Luís Quintanilha, Alexandre Santos-Silva, Alice |
author2_role |
author author author |
dc.contributor.none.fl_str_mv |
Veritati - Repositório Institucional da Universidade Católica Portuguesa |
dc.contributor.author.fl_str_mv |
Costa, Elísio Belo, Luís Quintanilha, Alexandre Santos-Silva, Alice |
dc.subject.por.fl_str_mv |
Haemodialysis Resitance to rhEPO therapy Erythropoietin Inflammation Leukocyte activation Iron status Erythrocyte damage |
topic |
Haemodialysis Resitance to rhEPO therapy Erythropoietin Inflammation Leukocyte activation Iron status Erythrocyte damage |
description |
Anaemia is a common complication in haemodialysis patients. This condition is associated to a decreased bone marrow production of erythrocytes, mainly due to the inability of the failing kidneys to secrete erythropoietin (EPO). The introduction of recombinant human EPO (rhEPO) therapy led to a significant reduction in anaemia and improved patients’ quality of life. However, there is a marked variability in the sensitivity to rhEPO, with up to 10-fold variability in dose requirements to achieve correction of anaemia. Approximately 5-10% of the patients show a marked resistance to rhEPO therapy. rhEPO resistance is associated to an increased morbidity and mortality of haemodialysis patients. In this paper a revision of the mechanisms underlying resistance to rhEPO therapy will be performed, with particular emphasis on inflammatory cytokines, leukocyte activation, iron status, and erythrocyte damage. |
publishDate |
2009 |
dc.date.none.fl_str_mv |
2009 2009-01-01T00:00:00Z 2010-10-16T16:46:14Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.14/3025 |
url |
http://hdl.handle.net/10400.14/3025 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
COSTA, Elísio; BELO, Luís - Resistance to recombinant human erythropoietin therapy in haemodialysis patients: Focus on inflammatory cytokines, leukocyte activation, iron status and erythrocyte damage. Journal of Nephrology and Renal Transplantation. ISSN 1918-025X. Vol. 2, n.º 3 (2009), p. 66–83 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
OmniScientia |
publisher.none.fl_str_mv |
OmniScientia |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799131715483992065 |